AMIE ALEXANDER: Open Payments
NPI 1104198266 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,762 in 138 payments from 16 companies in 2025. Trend: 2023 $1,581 · 2024 $2,832 · 2025 $2,762
Food & beverage: $2,762
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 37 | $740 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 21 | $357 |
| Janssen Biotech, Inc. | 18 | $353 |
| Lilly USA, LLC | 11 | $236 |
| Regeneron Healthcare Solutions, Inc. | 6 | $190 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $190 |
| Aimmune Therapeutics, Inc. | 9 | $184 |
| Ardelyx, Inc. | 6 | $129 |
| Gilead Sciences, Inc. | 5 | $97 |
| Celltrion USA Inc. | 4 | $84 |
Products named: TREMFYA, XIFAXAN, RINVOQ, OMVOH, CREON, DUPIXENT, ZENPEP, ENTYVIO.
Industry payments across MS — which companies pay providers there.
